Stockscreener 앱 받기
55.90
4.44%
-2.60
시간 외 거래:
56.06
0.16
+0.29%
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - Yahoo Finance Singapore
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - Yahoo Finance UK
ARWR6277444 Bond Profile: Coupon and Redemption - TradingView
Arrowhead Pharmaceuticals: The Fast-Follower Math Behind A $215 Million Voucher - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo Finance
Homozygous Familial Hypercholesterolemia (HoFH)7MM Market, Epidemiology, and Forecast2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities - GlobeNewswire Inc.
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock forecasts - au.finance.yahoo.com
Long term debt to total equity ratio of Arrowhead Pharmaceuticals, Inc. – HAN:HDP1 - TradingView
ETFs Investing in Arrowhead Pharmaceuticals, Inc. Stocks - TradingView
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Business Wire
Interim results from an experimental Alzheimer’s drug study will be presented Oct. 14. - Stock Titan
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies - Yahoo Finance
Arrowhead Achieves Clinical Validation for New Drug Platform - finance.yahoo.com
One experimental therapy silenced two genes at once. More results will follow at a medical congress. - Stock Titan
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia - Arrowhead Pharmaceuticals, Inc.
How Investors May Respond To Arrowhead Stock Phase 3 Trial Results - webull.com
Avoiding Lag: Real-Time Signals in (ARWR) Movement - Stock Traders Daily
ARWR Looks 63.8% Overvalued on GF Value™ - GuruFocus
Arrowhead Pharmaceuticals, Inc. (ARWR) Latest Stock News & Headlines - finance.yahoo.com
ARWR Initiated Coverage by Citigroup -- Price Target Announced a - GuruFocus
ARWR: SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 - Yahoo Finance
Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target - finance.yahoo.com
Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million - Yahoo Finance
Arrowhead Pharmaceuticals Inc. (ARWR) Key Financial Ratios – Valuation, Profitability & More - Value Research
Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label? - Yahoo Finance
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences - Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences - Yahoo Finance
Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe HypertriglyceridemiaSlideshow (NASDAQ:ARWR) 2026-09-02 - Seeking Alpha
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at European Society of Cardiology (ESC) Congress 2026Slideshow (NASDAQ:ARWR) 2026-09-02 - Seeking Alpha
ARWR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $120 - GuruFocus
Is Arrowhead Pharmaceuticals (ARWR) Undervalued As SHASTA 3 And SHASTA 4 Data Impress? - Yahoo Finance
Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says - marketscreener.com
Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 Trials - Yahoo Finance
Stifel reiterates Buy rating on Arrowhead Pharma stock at $104 - Investing.com
Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split - biospace.com
Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia - marketscreener.com
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Investing News Network
Arrowhead’s plozasiran cuts pancreatitis events in Phase 3 studies (ARWR:NASDAQ) - Seeking Alpha
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia - Arrowhead Pharmaceuticals, Inc.
Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating? - finance.yahoo.com
Arrowhead Pharmaceuticals Inc. (ARWR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress - Business Wire
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress - Arrowhead Pharmaceuticals, Inc.
Don't Ignore The Insider Selling In Arrowhead Pharmaceuticals - Moomoo
Arrowhead Pharmaceuticals director sells $173,920 in stock - Investing.com
Arrowhead Pharmaceuticals (ARWR) Director Adeoye Olukotun Sells 2,000 Shares - GuruFocus
Arrowhead (ARWR) Stock: Slides 3.28% to $86.47 in the Latest Reading; Technical Setup: the $82.15 to $90.79 Range Remains in Focus at the CloseHigh Dividend Factor - Vinanet
4.60%
자본화:
|
볼륨(24시간):